drugset / Trial / NCT02955628
RICE-ibrutinib in Relapsed DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.
Timeline
- Start
- 2016-12-13
- Primary completion
- 2023-08
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 560 mg | — |